Moderna Timeline
2010
Noubar Afeyan meets with Bob Langer and Derrick Rossi to review recent data on the use of chemically modified mRNA to reprogram adult human fibroblast cells into induced pluripotent stem cells following protocol of Prof. Yamanaka
2010
Noubar envisions a different use of engineered mRNA as a new kind of medicine and launches within Flagship’s VentureLabs group a month-long exploration which eventually leads to Newco LS18, Inc.
2010
LS18 starts experiments with novel chemical modifications of mRNA
2010
Initial protein expression experiments conducted in cell culture and foundational provisional patents filed by Flagship’s VentureLabs group in July and October 2010
2010
LS18 renames itself Moderna Therapeutics
2011
Noubar recruits Stéphane Bancel who joins Flagship as Senior Partner and LS18 board of directors in March 2011, becoming Moderna CEO in October 2011
2011
R&D team starts developing novel ways to design, synthesize and analyze synthetic mRNA and shows expression of therapeutic proteins in laboratory setting using cell lines
2011
- 2012
R&D team generates first ever data in mice, rats and later chimps showing proof of concept that engineered mRNA would lead to predictable and controllable production of therapeutic proteins they wouldn’t have otherwise made like growth hormones, EPO and VEGF
2013
Moderna partners with AstraZeneca to develop pioneering Messenger mRNA Therapeutics™ in cardiometabolic diseases and cancer
2013
DARPA awards Moderna a grant for up to $25 Million to develop Messenger RNA Therapeutics™
2014
Alexion Pharmaceuticals and Moderna Therapeutics announce exclusive strategic agreement to develop Messenger RNA Therapeutics™ for rare diseases
2014
Moderna launches Onkaido Therapeutics to focus on the development of mRNA Therapeutics™ in oncology with $20 million capital commitment
2015
License and collaboration agreement with Merck to develop mRNA-based antiviral vaccines and passive immunity therapies
2015
Moderna closes $450 million financing to support growth of Messenger RNA Therapeutics™ platform across diverse therapeutic areas
2016
Collaboration with PPD to support clinical development of novel mRNA Therapeutics
2016
Moderna transitions to a clinical stage company
2016
Initial grant of up to $20 million to advance mRNA-based antibody combination to help prevent HIV infection, through Valera, Moderna’s infectious disease-focused venture
2016
Collaboration with Merck to advance novel mRNA-based personalized cancer vaccines for the treatment of multiple types of cancer
2016
Vertex and Moderna establish exclusive collaboration to discover and develop mRNA Therapeutics™ for Cystic Fibrosis
2016
BARDA awards funding for $8 million with potential of up to $125 million to accelerate development of Zika Messenger RNA (mRNA) vaccine
2017
Positive interim Phase 1 clinical data demonstrates first mRNA vaccine candidate and induces high levels of immunogenicity
2017
First-in-human dosing for Phase 1 Study (KEYNOTE-603) of mRNA-4157, a personalized cancer vaccine, for the treatment of solid tumors
2018
Moderna opens new manufacturing site in Norwood, Mass.
2018
Moderna IPO on December 7 exceeds revised goal of $600 million by about $4.3 million, and the raise values the company at about $7.5 billion
2019
Positive interim Phase 1 data for first combination vaccine against the respiratory viruses hMPV and PIV3
2019
Publication of Phase 1 data for mRNA vaccines against two potential pandemic influenza strains
2019
FDA Fast Track designation for Zika vaccine mRNA-1893
2019
Positive interim results from Phase 1 cytomegalovirus (CMV) vaccine (mRNA-1647) study and progress toward Phase 2 and pivotal trials
2019
mRNA-3927, Moderna’s investigational mRNA therapeutic for propionic acidemia receives FDA Fast Track designation
January 2020
Stéphane Bancel asked if Moderna would be willing to do a phase 1 trial using mRNA and he and Noubar agree to proceed
February 2020
mRNA-1273 delivered from company’s cGMP facility in 42 days from sequence selection
March 2020
First participant dosed in NIH-led Phase 1 study of mRNA vaccine (mRNA-1273)
March 2020
First patient enrolled in Phase 1/2 study of mRNA-3704 for methylmalonic acidemia
April 16, 2020
Award from U.S. government agency BARDA for up to $483 million to accelerate development
May 1, 2020
Collaboration announced with Lonza Ltd to manufacture mRNA-1273 (goal of up to one billion doses per year)
May 12, 2020
FDA clearance to proceed with Phase 2 study of COVID vaccine
May 18, 2020
Announcement of positive interim data from Phase 1
May 29, 2020
First participant dosed in Phase 2 study
June 2020
Enrollment of Phase 2 study complete
July 14, 2020
Publication of positive interim Phase 1 data
July 27, 2020
Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273) begins
August 2020
Announces supply agreement with U.S. government for initial 100 million doses of COVID-19 vaccine
August 26, 2020
Presentation of older adults Phase 1 data
September 2020
Moderna slows enrollment to ensure Black, Latino, and Indigenous participants are represented in COVID vaccine trial
September 29, 2020
Publication of older adults Phase 1 data
September 2020
Moderna signs pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines
October 2020
Moderna pledges not to enforce COVID vaccine patents
October 2020
Enrollment of Phase 3 COVE study complete
November 15, 2020
Noubar received the news of the 94.5% efficacy and remembers the excitement of the first time seeing the data that mRNA worked with mice back in 2012
November 16, 2020
COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study
November 30, 2020
Primary efficacy analysis in Phase 3 COVE study for COVID-19 vaccine candidate is 94.1% and Moderna files with U.S. FDA for emergency use authorization